Abstract
Objective
To determine whether diabetes mellitus (DM) contributes to the drug resistance of carbamazepine (CBZ), we investigated the correlation between the blood glucose status and the CBZ resistance condition in patients with trigeminal neuralgia (TN).
Patients and methods
A total of 155 TN patients treated with the CBZ monotherapy were selected at Shanghai General Hospital and Shanghai Xinhua Hospital from September 2018 to January 2020. Among them, 15 were diagnosed with DM. Patients’ CBZ resistance levels were evaluated according to progression-free survival. We utilized ordered multiple classification logistic regression to determine the dominant factors leading to CBZ resistance. We analyzed the correlation between hemoglobin A1c (HbA1c) and progression-free survival using the Pearson correlation analysis.
Results
The regression analysis showed that DM was the only factor affecting CBZ resistance (p = 0.035; OR = 0.327; 95% CI, 0.115–0.926). Progression-free survival was 28.5 ± 21.2 months in the DM group and 66.0 ± 33.2 months in the non-DM group. The concentration of HbA1c in the blood was negatively correlated with progression-free survival (r = − 0.197; p = 0.014).
Conclusions
This study shows that blood glucose status is a significant factor contributing to the CBZ resistance in the treatment of TN. The progression-free survival of patients is affected by the status of DM and blood HbAlc levels.
Similar content being viewed by others
Data availability
Data is available upon reasonable request and with permission of Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine.
References
Burke WJ, Grant JM, Selby G (1965) The treatment of trigeminal neuralgia: a clinical trial of carbamazepine ("TEGRETOL"). Med J Aust 1:494–498
Collis JS Jr, Wallace TW (1968) Tic douloureux and diabetes mellitus. Cleve Clin Q 35:155–157. https://doi.org/10.3949/ccjm.35.3.155
Di Stefano G, La Cesa S, Truini A, Cruccu G (2014) Natural history and outcome of 200 outpatients with classical trigeminal neuralgia treated with carbamazepine or oxcarbazepine in a tertiary centre for neuropathic pain. J Headache Pain 15:34. https://doi.org/10.1186/1129-2377-15-34
Goebel A, Moore A, Weatherall R, Roewer N, Schedel R, Sprotte G (2003) Intravenous immunoglobulin in the treatment of primary trigeminal neuralgia refractory to carbamazepine: a study protocol [ISRCTN33042138]. BMC Neurol 3:1–1. https://doi.org/10.1186/1471-2377-3-1
Hagenacker T, Bude V, Naegel S, Holle D, Katsarava Z, Diener H-C, Obermann M (2014) Patient-conducted anodal transcranial direct current stimulation of the motor cortex alleviates pain in trigeminal neuralgia. J Headache Pain 15:78–78. https://doi.org/10.1186/1129-2377-15-78
Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38:1–211. https://doi.org/10.1177/0333102417738202
Hur YK, Choi IS, Cho JH, Park EJ, Choi JK, Choi BJ, Jang IS (2008) Effects of carbamazepine and amitriptyline on tetrodotoxinresistant Na+ channels in immature rat trigeminal ganglion neurons. Arch Pharm Res 31:178–182. https://doi.org/10.1007/s12272-001-1138-x
Jandova K, Pasler D, Antonio LL, Raue C, Ji S, Njunting M, Kann O, Kovacs R, Meencke HJ, Cavalheiro EA, Heinemann U, Gabriel S, Lehmann TN (2006) Carbamazepine-resistance in the epileptic dentate gyrus of human hippocampal slices. Brain 129:3290–3306. https://doi.org/10.1093/brain/awl218
Katusic S, Beard CM, Bergstralh E, Kurland LT (1990) Incidence and clinical features of trigeminal neuralgia, Rochester, Minnesota, 1945-1984. Ann Neurol 27:89–95. https://doi.org/10.1002/ana.410270114
Killian JM, Fromm GH (1968) Carbamazepine in the treatment of neuralgia. Use of side effects. Arch Neurol 19:129–136
Lechin F, van der Dijs B, Lechin ME, Amat J, Lechin AE, Cabrera A, Gómez F, Acosta E, Arocha L, Villa S (1989) Pimozide therapy for trigeminal neuralgia. Arch Neurol 46:960–963
Lu ZH, Liu N, Bai R, Yao Y, Li SN, Yu RH, Sang CH, Tang RB, Long DY, Du X, Dong JZ, Ma CS (2015) HbA1c levels as predictors of ablation outcome in type 2 diabetes mellitus and paroxysmal atrial fibrillation. Herz 40(Suppl 2):130–136. https://doi.org/10.1007/s00059-014-4154-6
Maarbjerg S, Di Stefano G, Bendtsen L, Cruccu G (2017) Trigeminal neuralgia - diagnosis and treatment. Cephalalgia 37:648–657. https://doi.org/10.1177/0333102416687280
Marshall K, Chan MD, McCoy TP, Aubuchon AC, Bourland JD, McMullen KP, deGuzman AF, Munley MT, Shaw EG, Tatter SB, Ellis TL (2012) Predictive variables for the successful treatment of trigeminal neuralgia with gamma knife radiosurgery. Neurosurgery 70:566–572; discussion 572-563. https://doi.org/10.1227/NEU.0b013e3182320d36
Mueller D, Obermann M, Yoon MS, Poitz F, Hansen N, Slomke MA, Dommes P, Gizewski E, Diener HC, Katsarava Z (2011) Prevalence of trigeminal neuralgia and persistent idiopathic facial pain: a population-based study. Cephalalgia 31:1542–1548. https://doi.org/10.1177/0333102411424619
Nurmikko TJ, Eldridge PR (2001) Trigeminal neuralgia--pathophysiology, diagnosis and current treatment. Br J Anaesth 87:117–132. https://doi.org/10.1093/bja/87.1.117
Rocamora R, Peltola J, Assenza G, McMurray R, Villanueva V (2019) Safety, tolerability and effectiveness of transition to eslicarbazepine acetate from carbamazepine or oxcarbazepine in clinical practice. Seizure 75:121–128. https://doi.org/10.1016/j.seizure.2019.12.022
Rockliff BW, Davis EH (1966) Controlled sequential trials of carbamazepine in trigeminal neuralgia. Arch Neurol 15:129–136. https://doi.org/10.1001/archneur.1966.00470140019003
Sanchez-Mejia RO, Limbo M, Cheng JS, Camara J, Ward MM, Barbaro NM (2005) Recurrent or refractory trigeminal neuralgia after microvascular decompression, radiofrequency ablation, or radiosurgery. Neurosurg Focus 18:e12
Saudek CD, Derr RL, Kalyani RR (2006) Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. Jama 295:1688–1697. https://doi.org/10.1001/jama.295.14.1688
Shen M, Lim JME, Chia C, Ren EC (2020) CD39 regulatory T cells modulate the immune response to carbamazepine in HLA-B*15:02 carriers. Immunobiology 225:151868. https://doi.org/10.1016/j.imbio.2019.11.003
Shimazaki T, Kadowaki T, Ohyama Y, Ohe K, Kubota K (2007) Hemoglobin A1c (HbA1c) predicts future drug treatment for diabetes mellitus: a follow-up study using routine clinical data in a Japanese university hospital. Transl Res 149:196–204. https://doi.org/10.1016/j.trsl.2006.09.008
Sjaastad O, Bakketeig LS (2007) The rare, unilateral headaches. Vaga study of headache epidemiology. J Headache Pain 8:19–27. https://doi.org/10.1007/s10194-006-0292-4
Takayama S, Osawa M, Takahashi Y, Iwamoto Y (2006) Painful neuropathy with trigeminal nerve involvement in type 2 diabetes. J Int Med Res 34:115–118. https://doi.org/10.1177/147323000603400115
Taylor JC, Brauer S, Espir ML (1981) Long-term treatment of trigeminal neuralgia with carbamazepine. Postgrad Med J 57:16–18. https://doi.org/10.1136/pgmj.57.663.16
Tesfaye S (2011) Recent advances in the management of diabetic distal symmetrical polyneuropathy. J Diabetes Investig 2:33–42. https://doi.org/10.1111/j.2040-1124.2010.00083.x
Wacker D, Wang C, Katritch V, Han GW, Huang XP, Vardy E, McCorvy JD, Jiang Y, Chu M, Siu FY, Liu W, Xu HE, Cherezov V, Roth BL, Stevens RC (2013) Structural features for functional selectivity at serotonin receptors. Science 340:615–619. https://doi.org/10.1126/science.1232808
Wiffen PJ, Derry S, Moore RA, McQuay HJ (2011) Carbamazepine for acute and chronic pain in adults. Cochrane Database Syst Rev:Cd005451. https://doi.org/10.1002/14651858.CD005451.pub2
Wiffen PJ, Derry S, Moore RA, Kalso EA (2014) Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev:Cd005451. https://doi.org/10.1002/14651858.CD005451.pub3
Xu Z, Zhang P, Long L, He H, Zhang J, Sun S (2016) Diabetes mellitus in classical trigeminal neuralgia: a predisposing factor for its development. Clin Neurol Neurosurg 151:70–72. https://doi.org/10.1016/j.clineuro.2016.10.015
Yagihashi S, Mizukami H, Sugimoto K (2011) Mechanism of diabetic neuropathy: where are we now and where to go? J Diabetes Investig 2:18–32. https://doi.org/10.1111/j.2040-1124.2010.00070.x
Zakrzewska JM, Patsalos PN (2002) Long-term cohort study comparing medical (oxcarbazepine) and surgical management of intractable trigeminal neuralgia. Pain 95:259–266
Acknowledgments
The authors acknowledge the collaboration of all of the staff and technical member at Department of Neurosurgery, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; Department of Neurosurgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; and Tongji University, Shanghai, China.
Funding
This research was funded by the National Natural Science Foundation of China (No. 81701359), the Natural Science Foundation of Shanghai (18ZR1430400), and the Cross Research Fund of Medicine and Engineering of Shanghai Jiaotong University (No. YG2016QN32, YG2019QNA67).
Author information
Authors and Affiliations
Contributions
Shaojian Lin conceived the original idea and Lili Wei developed the theoretical framework. All authors contributed to the interpretation of the results. All authors discussed the results and contributed to the final version of the manuscript. All authors read and approved the final manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare that they have no competing interests.
Ethical approval and consent to participate
The study was conducted in accordance with local laws. Since it was a retrospective study, there was no need to sign an informed consent.
Consent for publication
Not applicable.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Anke Zhang, Wenbo Zhang, and Houshi Xu are co-first authors to the article
Rights and permissions
About this article
Cite this article
Zhang, A., Zhang, W., Xu, H. et al. Diabetes mellitus contributes to carbamazepine resistance in patient with trigeminal neuralgia. Neurosurg Rev 44, 1119–1125 (2021). https://doi.org/10.1007/s10143-020-01304-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10143-020-01304-4